Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Takeda Taking Steps for 10-Fold Increase in China Revenues

publication date: May 16, 2011
Takeda Pharma of Japan wants to grow its China revenues by more than 10 times before the end of 2015, according to the company’s President, Yasuchika Hasegawa. It currently produces  3 billion yen ($37 million) of sales in the PRC. To accomplish its goals, the company will invest “several tens of billions of yen” in China over the next few years – with each ten billion yen worth about $124 million. Takeda will also increase its sales force from 250 representatives to 900. More details....

Stock Symbol: (TO: 4502)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital